CoChat

NEWBORN SCREENING FOR CONGENITAL ADRENAL HYPERPLASIA

Therrell, Bradford L. · 2001 · Endocrinology and Metabolism Clinics of North America

The DOI matches its Crossref record; 42 of the 45 references it cites were found in a registry or an index.

Abstract

Classic CAH (salt-wasting and simple virilizing) meets all of the recommended criteria for newborn screening. There are reliable and efficient newborn screening tests, the disorder results in high morbidity and mortality if left undetected, there is effective treatment that reduces negative outcomes, and there is a relatively high incidence. When compared with the case findings without the benefit of screening, the data from screening programs show reduced adrenal crises, reduced incorrect sex assignments, and reduced deaths. Racial/ethnic prevalence differences are present in newborn screening program data. The Texas data indicate a lower disease frequency in African-Americans when compared with Caucasians, and international data indicate higher frequencies in native Yupik Eskimos, Brazilians, residents of La Reunion, and Filipinos. When worldwide clinical ascertainment data are compared with newborn screenng data, it is clear that newborns with CAH (especially males) die when screening is not done. To be effective in reducing mortality, newborn screening must be performed soon after birth, and the results must be available quickly so that early salt-wasting crises can be averted. It is preferable that newborn screening laboratiories be operational 7 days a week, and that sample delivery from the collection site to testing laboratory be as efficient as possible, including weekends and holidays, so that undue testing delays are not encountered. These two requirements pose major challenges for most programs, but they are critical to optimal screening outcome. Based on the studies in Texas, with second screening samples collected at approximately 2 weeks of age, some newborns with simple virilizing CAH are missed on initial screening using current testing protocols. There is need to set a screening cut-off such that the false-positive rate does not oversaturate the follow-up system, in part owing to the insensitivity of current kit methodologies and the biochemical manifestations of CAH. With advances in genetic testing procedures and improved automation techniques, it may soon be possible for CAH screening programs to include genotyping as a second-tier confirmation as a part of the newborn screening protocol. Despite the fact that CAH is a continuum of disorders, the correlation between genotype and phenotype is fairly consistent in most cases. For the purpose of screening, genotyping will likely be useful only for differential diagnoses of non-salt wasters, given the necessary time constraints and expense of obtaining genotypes and the need for immediate diagnosis/treatment of salt wasters. It is hoped that newborn screening programs will begin to provide answers to some of these question in addition to their primary function of reducing the morbidity and mortality resulting from CAH.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0889-8529(08)70017-3

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Therrell, 1992, Screening for congenital adrenal hyperplasia—the need for uniform data collection, Infant Screening, 15, 18

Cited by

See all 221

Metadata

Authors
Therrell, B. L.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
Corresponding author
Therrell, Bradford L.
Venue
Endocrinology and Metabolism Clinics of North America
Publisher
Elsevier BV
Published
2001-03
Volume
30
Issue
1
Pages
15-30
ISSN
0889-8529 (ISSN-L)
OpenAlex
W1992545726
Cited by
221
References
45
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 12 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 9 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 5 · 2013: 7 · 2012: 9
FWCI
3.03
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Endocrinology and Metabolism Clinics of North America (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
congenital adrenal hyperplasia, newborn screening, salt-wasting CAH, simple virilizing CAH, adrenal crisis, gender assignment, screening cut-off values, false positive rate, genotyping, genotype-phenotype correlation
MeSH terms
Adrenal Hyperplasia, Congenital, Female, Humans, Infant, Newborn, Male, Paper, Sensitivity and Specificity, Neonatal Screening, 17-alpha-Hydroxyprogesterone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NEWBORN SCREENING FOR CONGENITAL ADRENAL HYPERPLASIA. https://app.cochat.ai/papers/10.1016/s0889-8529(08)70017-3
The paper
Therrell, B. L. (2001). NEWBORN SCREENING FOR CONGENITAL ADRENAL HYPERPLASIA. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/s0889-8529(08)70017-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.